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Abstract
Background: TDP-43 proteinopathies are characterized by loss of nuclear TDP-43 expression and formation of C-
terminal TDP-43 fragmentation and accumulation in the cytoplasm. Recent studies have shown that TDP-43 can
accumulate in RNA stress granules (SGs) in response to cell stresses and this could be associated with subsequent
formation of TDP-43 ubiquinated protein aggregates. However, the initial mechanisms controlling endogenous
TDP-43 accumulation in SGs during chronic disease are not understood. In this study we investigated the
mechanism of TDP-43 processing and accumulation in SGs in SH-SY5Y neuronal-like cells exposed to chronic
oxidative stress. Cell cultures were treated overnight with the mitochondrial inhibitor paraquat and examined for
TDP-43 and SG processing.
Results: We found that mild stress induced by paraquat led to formation of TDP-43 and HuR-positive SGs, a
proportion of which were ubiquitinated. The co-localization of TDP-43 with SGs could be fully prevented by
inhibition of c-Jun N-terminal kinase (JNK). JNK inhibition did not prevent formation of HuR-positive SGs and did
not prevent diffuse TDP-43 accumulation in the cytosol. In contrast, ERK or p38 inhibition prevented formation of
both TDP-43 and HuR-positive SGs. JNK inhibition also inhibited TDP-43 SG localization in cells acutely treated with
sodium arsenite and reduced the number of aggregates per cell in cultures transfected with C-terminal TDP-43
162-414 and 219-414 constructs.
Conclusions: Our studies are the first to demonstrate a critical role for kinase control of TDP-43 accumulation in
SGs and may have important implications for development of treatments for FTD and ALS, targeting cell signal
pathway control of TDP-43 aggregation.
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Background
Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset
neurodegenerative disease in which the function of
motor neurons in the spinal cord and brain progres-
sively deteriorates. ALS is by far the most prevalent
form of motor neuron disease. Patients with ALS rarely
survive more than 3-5 years after diagnosis with
respiratory failure the most common cause of death [1].
Approximately 5% of patients with ALS have a positive
family history of the disorder. The first pathological
mutations identified in ALS were in superoxide dismu-
tase 1 (SOD1) and account for around 20% of familial
ALS cases [2]. That discovery has been the basis for
most ALS research in the past decade, and animal mod-
els containing SOD1 mutant transgenes have provided
important insights into SOD1-mediated neurotoxic
effects. However, SOD1 mutations only account for 1-
2% of all ALS cases [3].
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common cause of presenile dementia, affecting people
in their 50s and 60s [4,5]. There are several clinical phe-
notypes and the historical neuropathological classifica-
tion included either frontotemporal lobar degeneration
with tau positive (FTLD-tau) or ubiquitin-positive
(FTLD-U) inclusions [4,5]. The observation that some
ALS patients developed cognitive deficits with frontal
lobe degeneration resembling FTLD-U has led to the
belief that ALS and FTD with FTLD-U might involve a
clinical spectrum of neurodegenerative illnesses [5].
In 2006, TAR DNA binding protein 43 (TDP-43) was
identified as the major protein constituent of ubiquiti-
nated neuronal inclusions in FTLD-U and in non-SOD1
ALS cases [6,7]. This led to the re-classification of
FTLD-U to FTLD-TDP-43, and TDP-43-positive ALS
and FTLD-TDP-43 cases are now referred to collectively
as primary TDP-43 proteinopathies [8]. These findings
also provided further support for the concept of FTD
and ALS as diseases within the same broad clinical spec-
trum. Subsequently, TDP-43-positive inclusions have
been identified in a number of neurodegenerative dis-
eases. In these cases, the TDP-43 identification is
referred to as a secondary TDP-43 proteinopathy [8].
While the role of abnormal TDP-43 accumulation in
both primary and secondary TDP-43 proteinopathies is
not yet fully understood, the identification of TDP-43
mutations associated with ALS and FTD (~40 at pre-
sent) has provided clear evidence that altered TDP-43
processing can be a primary cause of neurodegeneration
and is not just a secondary phenomenon [9,10].
TDP-43 is a 414 amino acid protein of the heteroge-
neous nuclear ribonucleoprotein (hnRNP) family and
consists of two RNA recognition motifs and a C-term-
inal glycine rich region [8,11]. It has a number of
reported roles including transcription, pre-mRNA spli-
cing, and transport and stabilization of mRNA [8]. The
protein is normally localized to the nucleus and has a
classical bipartite nuclear localization sequence [12].
TDP-43 contains two caspase 3 consensus cleavage sites
leading to formation of C-terminal fragments (CTFs) of
35 kDa and 25 kDa that are excluded from the nucleus
[8]. The majority of TDP-43 mutations occur in the C-
terminal region and CTFs are commonly identified in
ALS and FTD inclusions.
In post-mortem tissue from ALS and FTD, the hall-
mark neuropathological features include loss of TDP-43
expression in the nucleus together with accumulation of
TDP-43 in cytoplasmic inclusions. These inclusions are
enriched in ubiquitinated and hyperphosphorylated
(phospho-Ser409/410) TDP-43 and there can be sub-
stantial enrichment of CTF-TDP-43 [8,11]. Recent cell
studies have shown that transfection with CTF-TDP-43
can accurately re-capitulate the histopathological
findings of ALS and FTD with accumulation of cytosolic
ubiquitinated and phosphorylated CTF-TDP-43 aggre-
gates [13-15]. In addition, transfection with these con-
structs can result in neurotoxicity and cell death
although the pathways involved are not known [14].
However, while these studies have recapitulated find-
ings of post-mortem disease tissue, they have told us lit-
tle of the early disease processes associated with
abnormal TDP-43 metabolism, particularly in sporadic
TDP-43 proteinopathies which account for > 90% of
ALS (and FTD) cases. A new insight into TDP-43 accu-
mulation is developing through studies identifying TDP-
43 association with RNA stress granule proteins [16,17].
Stress granules (SGs) are cytoplasmic sites of stalled
mRNA pre-initiation complexes induced by oxidative
changes, heat shock or osmotic stress where the cell
stalls mRNA translation of non-critical proteins to shift
energy expenditure to key repair and survival proteins
[18]. Recent studies have shown that under stress, TDP-
43 is recruited to SGs in a variety of cells [16,17,19,20].
I n i t i a l l yM o i s s ee t .a l .[ 2 1 ]r e p o r t e dt h a tT D P - 4 3l o c a -
lized to SGs after axotomy in mice. Subsequently, stu-
dies in cells revealed that acute cell stress induced TDP-
43 SG association and this was dependent on residues
216-315 and the first RNA recognition motif [19]. While
the same group reported a lack of TDP-43 association
with SG markers in ALS tissues, subsequent work by
Volkening et al. [22] reported an association between
TDP-43 and staufen in ALS spinal cord tissue. TDP-43
SG co-localization in ALS and FTLD-U has since been
reported by Liu-Yesucevitz et al., [17] and FUS, another
hnRNP protein associated with ALS, has also been iden-
tified in ALS SGs [23,24]. Liu-Yesucevitz et al. [17] also
reported that TDP-43 may associate with SGs through
interaction with SG proteins such as TIA-1 and this has
been supported by studies on TDP-43 association with a
number of SG proteins [20,25]
However, while these studies have advanced our
understanding of the early stages of TDP-43 aggrega-
tion, the majority of this research has been performed in
cells exposed to acute and highly toxic treatment with
sodium arsenite, the standard means of inducing SGs
[17,19,20]. In addition, much of our knowledge has been
gained through generation of CTF-TDP-43 over-expres-
sion in transfected cells. There is a lack of understand-
ing about the processes involved in endogenous TDP-43
aggregation during chronic oxidative stress. As the
majority of ALS and FTD cases involve no known muta-
tion in TDP-43 and the slow disease process characteris-
tic of neurodegeneration involves chronic oxidative and
nitrosative stresses [2,26], it is critical to determine how
these factors affect TDP-43 SG cytosolic accumulation.
Moreover, SG proteins have a high propensity to aggre-
gate and over-expression of highly aggregating CTF
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ing mechanistic processes involved in endogenous TDP-
43 aggregation and association with SGs during chronic
stress. Therefore, we investigated the effects of mild,
chronic oxidative and nitrosative stress on endogenous
TDP-43 in neuronal-like cell cultures. Our findings
revealed that in contrast to acute stress, chronic oxida-
tive stress induced several features consistent with TDP-
43 proteinopathies including loss of nuclear TDP-43,
accumulation of diffuse TDP-43 in the cytosol, forma-
tion of a 35 kDa C-terminal fragment and accumulation
of TDP-43 in SGs, some of which revealed ubiquitina-
tion. Importantly, our findings revealed that TDP-43
localization to SGs was controlled by c-Jun N-terminal
kinase (JNK). Inhibition of JNK also modulated TDP-43
accumulation in SGs induced by sodium arsenite and in
cells transfected with CTF-TDP-43 constructs. Our data
also indicated that the aggregation of TDP-43 may be
associated with JNK modulation of hnRNP-TDP-43
interactions and SG localization.
Results
To investigate the effects of chronic stress on TDP-43
metabolism, we first determined optimal concentrations
of oxidative and nitrosative stress inducers in SH-SY5Y
neuronal-like cultures. Cells were treated overnight with
each compound at a range of concentrations and the cell
viability was determined by MTT assay and cell death
was measured using an LDH assay (not shown). Addi-
tional File 1 shows the selected concentrations used for
further investigation. The concentrations shown in Addi-
tional File 1 induced mild but significant reductions in
cell viability overnight. However, except for 2 mM para-
quat (24 ± 3.2% cell death) and 75 μM rotenone (32 ±
4.6% cell death), no change to LDH release was observed
compared to untreated controls. These doses were used
to mimic sub-lethal chronic stress conditions relevant to
brain or spinal cord neurons during disease in vivo.
Nitrosative stress inducers mediate altered TDP-43
processing
Treatment of SH-SY5Y cells with inducers of nitrosative
stress resulted in changes to sub-cellular distribution of
TDP-43. Compared to untreated controls (Figure 1A-C),
SIN-1, a peroxynitrite donor caused a frequent, evenly
distributed, diffuse accumulation of TDP-43 in the cyto-
sol of treated cells (Figure 1D-F). In contrast, paraquat,
an inhibitor of the mitochondrial electron transport
chain and inducer of superoxide/peroxynitrite stress (a
common feature in neurodegeneration), induced sub-
stantial and varied cytoplasmic accumulation of TDP-43
including aggregates of TDP-43 resembling RNA SGs
(Figure 1G-I). Arginine (nitric oxide precursor) had no
consistent effect (Figure 1J-L).
Paraquat induces a robust cell model of TDP-43
proteinopathy
Further examination of TDP-43 in paraquat-treated cells
revealed multiple features reported for human TDP-43
proteinopathies. Paraquat-treated cells frequently
showed clear loss of nuclear TDP-43 (Figure 2D-F),
accumulation of diffuse TDP-43 in the cytosol (Figure
2G-I) and formation of cytoplasmic aggregates. Interest-
ingly, these changes were not always observed in the
same cells suggesting that loss of nuclear TDP-43
expression and accumulation in the cytosol may been
caused by different stress-mediated processes. To deter-
mine if the cytosolic aggregates of TDP-43 induced by
paraquat were SGs, cells were co-stained for the SG
marker, HuR. The majority of TDP-43 aggregates co-
localized with HuR although there were also additional
HuR-positive SGs that lacked TDP-43 (Figure 2N-Q).
Quantitative analysis revealed that 66 ± 8% of paraquat-
induced SGs that were positive for HuR were also posi-
tive for TDP-43 and that SG formation correlated to
increasing toxicity of paraquat (Additional File 2). TDP-
43 also frequently co-localized with the SG marker,
TIA-1 (data not shown). We examined the time course
of TDP-43 SG formation and found that TDP-43 only
accumulated into SGs between 8 and 20 hr after expo-
sure to paraquat. This is in contrast to the rapid accu-
mulation of TDP-43 into SGs reported for arsenite or
osmotic stress [19,20]. Our findings were also observed
in retinoic-acid differentiated SY5Y neuronal-like cells,
confirming that these changes can occur in non-dividing
SY5Y cells (Additional File 2H-K).
We extended the investigation of this model further
by examining if TDP-43-positive SGs revealed presence
of the protein aggregate marker ubiquitin, also a hall-
mark feature of the ubiquitinated inclusions in ALS and
FTLD-U in FTD. Interestingly, our study revealed that a
number of the TDP-43-positive SGs co-localized with
ubiquitin (Figure 3F and 3J). 24 ± 6% of TDP-43-posi-
tive SGs were also positive for ubiquitin indicating that
only a portion of the SGs may progress to ubiquitinated
protein aggregates (Figure 3). Diffuse TDP-43 did not
consistently co-localize with ubiquitin (Figure 3J).
Whether the ubiquitination of the SGs was associated
directly with the TDP-43 or ubiquitination of alternative
SG proteins is uncertain. Due to the relatively low num-
bers of cells containing ubiquitinated SGs and lack of a
method for purifying SGs, it was not possible to deter-
mine if the ubiquitinated protein in the SGs was specifi-
cally TDP-43.
Interestingly, we did not observe phosphorylated TDP-
43 associated with the SGs (Additional File 3A-F). This
was confirmed by Western blot analysis that detected
no increase in phosphorylated TDP-43 or phosphory-
lated CTF-TDP-43 post-exposure to paraquat
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Figure 1 Effect of SIN-1, paraquat and arginine on TDP-43 localization in SH-SY5Y cells. Cells were exposed overnight with 0.1 mM SIN-1,
1 mM paraquat or 1 mM arginine and TDP-43 localization was examined by immunofluorescence. A-C: untreated, D-F: SIN-1, G-I: paraquat, J-L:
arginine. Green = TDP-43, blue = DAPI. Right-hand panel = merged images of TDP-43 and DAPI. Arrowheads show diffuse cytosolic TDP-43.
Arrows show aggregated cytosolic TDP-43. Bar = 10 μm. Representative images from three separate experiments performed in duplicate or
triplicate.
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Figure 2 Induction of cytosolic TDP-43 accumulation and SGs by paraquat in SH-SY5Y cells. Cells were exposed overnight to 1 mM
paraquat and TDP-43 localization was examined by immunofluorescence. A-C: untreated, D-I: paraquat treated. Arrows show loss of nuclear
TDP-43. Arrowheads show diffuse cytosolic TDP-43. Green = TDP-43, blue = DAPI. Right-hand panels = merged images. J-Q: Cells were exposed
to 1 mM paraquat overnight and TDP-43 and HuR localization was measured by immunofluorescence. J-M: untreated, N-Q: paraquat treated.
Green = TDP-43, Red = HuR, Blue = DAPI. M and Q are merged images from TDP-43 and HuR panels. Arrows indicate stress granules. Inset
shows higher magnification of TDP-43 and HuR positive SGs. Bar = 10 μm. Representative images from four separate experiments performed in
duplicate or triplicate.
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Figure 3 Treatment of SH-SY5Y neurons induces co-localization of TDP-43 and ubiquitin in SGs. Cells were treated overnight with 1 mM
paraquat and localization of TDP-43 and ubiquitin was determined by immunofluorescence. A-D: untreated, E-L: paraquat treated. Green = TDP-
43, red = ubiquitin, blue = DAPI. D, H and L represent merged images of panels above. Solid arrows indicate co-localization of TDP-43 and
ubiquitin in SGs. Arrowhead indicates lack of co-localization of TDP-43 and ubiquitin in one SG in panel F. Dotted arrow indicates lack of co-
localization of diffuse TDP-43 and ubiquitin. Bar = 10 μm. Representative images from three separate experiments performed in duplicate or
triplicate.
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treatment of cells is required to induce phosphorylation
or that the correct cellular kinases are not present or
not-localized to SGs. Alternatively the TDP-43 may be
phosphorylated on sites different to the 409/410 site.
However, the combination of clear nuclear loss of TDP-
43, diffuse cytosolic accumulation, aggregation and ubi-
quitination under mild stress provided a unique model
for investigating the early processes in abnormal TDP-
43 processing associated with ALS and FTD.
Paraquat induces formation of caspase-dependent and
caspase-independent TDP-43 SGs
One of the hallmark neuropathological features of TDP-
43 proteinopathies is the formation of C-terminal TDP-
43 fragments (CTF-TDP-43), often of 35 or 25 kDa in
mass [6,8]. Cell studies have re-capitulated features of
end-stage TDP-43 proteinopathies through expression
of these fragments which aggregate and co-localize with
SG proteins [13,27]. Therefore, we examined if our
paraquat model also induced CTF-TDP-43. The SH-
SY5Y cells revealed basal expression of a 35 kDa TDP-
43 band even in untreated cultures. This is consistent
with previous observations [28]. Western blot analysis of
paraquat-treated cells revealed the increased expression
of this 35 kDa CTF-TDP-43 (Figure 4A). Interestingly,
none of the additional mitochondrial inhibitors or nitro-
sative stress inducers tested significantly elevated 35
kDa CTF-TDP-43 (Figure 4A and 4B). This was despite
inducing a similar loss of cell viability (Additional
File 1). These findings suggested that formation of TDP-
43 SGs may be specifically associated with CTF-TDP-43
as previously supported by studies involving transfection
of cells with TDP-43 CTF constructs [16]. Co-treatment
of cells with paraquat and the broad-spectrum caspase
inhibitor, Z-VAD-fmk, resulted in a complete inhibition
of increased 35 kDa CTF-TDP-43 expression (Figure
4C). This supported previous studies demonstrating that
35 kDa TDP-43 CTFs are generated by caspase-cleavage
at a DETD consensus site within the NLS of TDP-43
[29,30]. However, we found that while inhibiting CTF-
TDP-43 generation with Z-VAD-fmk partially inhibited
TDP-43 SG formation (Figure 4H), the effect was not
complete. Treatment of cultures with Z-VAD-fmk
reduced the number of cells containing TDP-43-positive
SGs from 18 ± 8% to 8 ± 2% (P < 0.05). This inhibitory
effect was mainly due to a reduction in cells containing
s m a l l e rT D P - 4 3 - p o s i t i v eS G sa st h e r ew a sn ol o s so f
large (≥ 1 μm) TDP-43 SGs in Z-VAD-fmk treated cells,
despite a complete inhibition of enhanced 35 kDa CTF
formation. In our cultures, no change was observed to a
faint 25 kDa CTF-TDP-43 (Figure 4C), ruling out invol-
vement of this fragment in TDP-43 SG formation.
Nishimoto et al. have also reported that the 25 kDa
form is not involved in TDP-43 SG formation [30].
These findings strongly suggest that while paraquat
treatment enhanced 35 kDa CTF-TDP-43 formation,
this was not sufficient for TDP-43 SG formation.
Induction of cytosolic TDP-43 accumulation by paraquat
is not mediated through mitochondrial inhibition
As paraquat is a mitochondrial electron transport chain
inhibitor, we compared paraquat treatment with alterna-
tive inhibitors of cellular respiration to determine if
mitochondrial impairment induced TDP-43 SGs. Figure
5P-R shows that only paraquat induced cytosolic accu-
mulation and formation of TDP-43-positive SGs after an
overnight treatment. Other mitochondrial inhibitors
including rotenone (Figure 5D-F), 3-NP (Figure 5G-I),
MPP+ (Figure 5J-L) and sodium azide (Figure 5M-O)
h a dn oe f f e c to nT D P - 4 3d e s p i t eb e i n ga p p l i e da tc o n -
centrations that induced the same or increased level of
mild cell toxicity (Additional File 1). We then deter-
mined if the alternative mitochondrial respiration inhibi-
tors induced HuR-positive SGs that lacked TDP-43.
However, as shown in Additional File 4, no HuR-posi-
tive SGs were observed in cells after overnight treatment
with the mitochondrial inhibitors. These observations
showed that the ability of paraquat to induce loss of
nuclear TDP-43, cytosolic accumulation and SGs is not
solely attributable to its ability to inhibit mitochondrial
activity per se. These findings suggest that the effects of
paraquat on TDP-43 are more likely associated with
specific pathways of oxidative or nitrosative stress
induction that differ from the other mitochondrial
inhibitors.
JNK controls TDP-43 localization to SGs during
oxidative stress
It has been reported previously that kinases can control
cytoplasmic localization and SG accumulation of
hnRNPs such as hnRNP A1 and hnRNP K. This
includes p38, JNK and ERK-dependent modulation of
hnRNP sub-cellular accumulation [31-36]. Of these, JNK
has been clearly established as a critical stress-activated
kinase [37] and is central to toxic effects of paraquat
[38,39]. Therefore, we examined if modulation of JNK
activity affected TDP-43-positive SG formation. Initially,
we determined if paraquat induced activation of JNK
and p38 as previously reported [38]. After overnight
treatment with 1 mM paraquat robust activation of JNK
and ERK was observed with weaker p38 activity (Figure
6A). A time course of activation revealed elevated JNK
and ERK phosphorylation after 30-60 min with maximal
activation at 2 hr (Figure 6A). No early activation of p38
was observed (data not shown). Subsequent co-treat-
ment of cultures with paraquat and the JNK inhibitor,
SP600125, resulted in almost complete inhibition of
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Figure 4 Paraquat treatment induces up-regulation of a caspase-dependent TDP-43 fragment. SH-SY5Y cells were treated overnight with
1 mM paraquat, 1 mM arginine, 100 μM SIN-1 (A), or 1 mM paraquat, 2 mM MPP+, 0.075 mM rotenone (B) and TDP-43 expression was
determined by immunoblot. C: Cells were treated overnight with 1 mM paraquat with and without 50 μM Z-VAD-fmk (caspase inhibitor) and
TDP-43 expression was determined by immunoblot. Middle panels represent a longer exposure to visualize the 35 kDa band. D-I: Cells were
treated overnight with paraquat in the absence (F-G) and presence (H-I) of Z-VAD-fmk and examined for TDP-43-positive SGs. Green = TDP-43,
Blue = DAPI. Arrows indicate TDP-43-positive SGs ≤ μm. Arrowheads indicate TDP-43-positive SGs ≥ 1 μm. Bar = 10 μm. Representative images
from two-three separate experiments.
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of HuR-positive SGs (Figure 6B and 6C-R). This was
paralleled by inhibition of JNK phosphorylation (Addi-
tional File 4K). The numbers of SGs per cell was used
as a more consistent indicator than total number of
cells containing SGs. However, in paraquat-treated cul-
tures, the number of cells containing one or more TDP-
43-positive SGs was 18 ± 8% of all cells. Co-treatment
with SP600125 and paraquat reduced this to 0.22 ±
0.06% of cells (P < 0.01). No cells containing SGs were
observed in control cultures.
As SP600125 is not entirely specific for JNK, we also
tested the effect of BI-78D3, a specific JNK inhibitor
on TDP-43 SG formation [40] and found that this
induced the same effect as SP600125 (data not shown).
This was further supported by the fact that inhibition
of another SP600125 target kinase, casein kinase 1
(CK1) with a CK1 inhibitor (D4476), had no effect on
TDP-43 or HuR SG formation (Figure 6B). Additional
confirmation of the specific role for JNK in TDP-43
accumulation in stress granules was obtained through
JNK knockdown. Treatment with combined siRNA
against JNK1 and JNK2 significantly reduced JNK
expression (Additional File 5A). Subsequent treatment
with paraquat resulted in almost no TDP-43-positive
stress granules while still inducing HuR-positive stress
granules (Additional File 5B-M).
In contrast, inhibition of ERK with PD98059 had a
substantial inhibitory effect on both TDP-43 and HuR-
positive SG formation (Figure 6B and Figure 7I-L com-
pared to A-D). In paraquat-treated cultures, 27.4 ± 7%
of cells contained HuR-positive SGs (no HuR-positive
SGs were observed in control cultures). This was
reduced to 1.5 ± 0.3% after treatment with PD98059 (P
< 0.01). A parallel decrease in the number of cells con-
taining TDP-43-positive SGs was observed (reduced
from 18 ± 8% to 0.99 ± 0.2% of cells, P < 0.01). These
effects were also confirmed using the additional ERK
inhibitor, U0126 and Raf inhibitor, GW5074 (data not
shown). A somewhat weaker effect was observed on
TDP-43 and HuR SG formation by SB203580, an inhibi-
tor of p38 (Figure 6B and Figure 7M-P compared to A-
D). SB203580 reduced the number of cells containing
HuR-positive SGs from 27.4 ± 7% to 12.9 ± 1.7% (P <
0.01) and cells containing TDP-43-positive SGs from 18
± 8 to 7.2 ± 2.1% (P < 0.01). Although ERK was acti-
vated earlier than p38 by paraquat, the inhibition of
HuR and TDP-43-positive SGs by inhibitors of both
kinases is consistent with our observations that SGs
were not detected until after 8 hr of paraquat exposure
(data not shown). This suggests that different kinases
m a yh a v ear o l ei nS Gf o r m a t i o no v e rt h ep r o l o n g e d
exposure to paraquat with JNK controlling TDP-43
association and ERK and p38 affecting TDP-43 and
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Figure 5 Treatment of SH-SY5Y cells with different mitochondrial inhibitors did not induce TDP-43 aggregation. Cells were treated with
vehicle control (A-C), 0.075 mM rotenone (D-F), 1 mM 3-NP (G-I), 2 mM MPP+ (J-L), 5 mM sodium azide (M-O) or 1 mM paraquat (P-R). Cells
were analyzed for TDP-43 localization by immunofluorescence. Green = TDP-43, blue = DAPI. C, F, I, L, O and R represent merged images of
adjacent TDP-43 and DAPI panels to the left. Arrows indicate TDP-43 SGs in paraquat-treated cells. Bar = 10 μm. Representative images from
three separate experiments performed in duplicate or triplicate.
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Figure 6 Treatment of SH-SY5Y cells with paraquat induces JNK-dependent accumulation of TDP-43 into SGs. Cells were treated with 1
mM paraquat overnight. Where indicated, cells were co-treated with 10 μM SP600125 (JNK inhibitor), PD98059 (ERK inhibitor), SB203580 (p38
inhibitor) or D4476 (CK1 inhibitor). Cells were examined for phosphorylation of kinases by immunoblot and accumulation of TDP-43 and HuR by
immunofluorescence. A: Cells were treated with paraquat and examined after overnight incubation for activation of JNK, p38 and ERK. In
addition, cells were incubated with paraquat and examined at different time points from 0-480 min (8 hr) for ERK and JNK activation. Lower
panels for each image indicate that total kinase expression is unchanged, upper panels indicate changes to phorphorylated forms. B: Cells were
treated with paraquat in the presence or absence of kinase inhibitors and the number of TDP-43 and HuR SGs was determined. *p < 0.05, **p <
0.01. n = minimum of 500 cells counted across multiple coverslips and separate experiments for each inhibitor. C-F: Untreated, G-J: Paraquat
treated, K-N: Paraquat + SP600125 showing loss of TDP-43 but not HuR SGs, O-R: Paraquat + SP600125 showing loss of TDP-43 SGs but not
diffuse cytosolic TDP-43. Green = TDP-43, red = HuR, blue = DAPI. Bottom panels indicate merged images of TDP-43 and HuR panels above.
Arrows indicate SGs, arrowheads indicate diffuse TDP-43. Bar = 10 μm. Representative images from two-four separate experiments performed in
duplicate or triplicate.
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report of JNK and additional kinases controlling TDP-
43 localization to SGs. The fact that inhibition of JNK
resulted in almost complete abrogation of TDP-43-posi-
tive SGs with little effect on HuR localization to SGs
indicated that JNK is potentially a key controller of
TDP-43 (and possibly other hnRNP) association with
SGs rather than simply mediating SG formation per se.
As the majority of studies on SGs involve acute (0.5 -
1 hr) treatment with toxic doses of stress inducers such
as arsenite, heat shock or osmotic stress, we examined
whether a short-term treatment with paraquat induced
JNK-controlled TDP-43 SG formation. Interestingly
treatment of cells for 1 hr with up to 5 mM paraquat
had no effect on HuR or TDP-43 (data not shown),
demonstrating that paraquat-mediated SG formation is
a longer term process requiring prolonged incubation
for TDP-43 to localize to SGs. The data are more con-
sistent with a role for paraquat in prolonged oxidative
stress than impairment of mitochondrial function and
suggest that paraquat or other chronic inducers of TDP-
43 SG formation may provide useful models to mimic
the slow progression of disease-associated changes in
ALS or FTD.
JNK controls TDP-43 SG association in different cell-types
To determine if the effect of JNK inhibition on TDP-43
localization with SGs in SH-SY5Y cells was specific for
this cell-type, we compared this to additional cell-lines
treated with paraquat. Treatment of HeLa cells and
U87MG glial cells overnight with 1 mM paraquat
resulted in TDP-43-positive SGs (Additional File 6).
Extensive numbers of TDP-43 SGs were observed in
HeLa cells (~28% of cells) while SG positive cells in
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Figure 7 Treatment of SH-SY5Y cells with paraquat induces ERK and p-38-dependent accumulation of TDP-43 and HuR-positive SGs.
Cells were treated overnight with 1 mM paraquat in the absence or presence of 10 μM PD98059 (ERK inhibitor), SB203580 (p38 inhibitor) or
SP600125 (JNK inhibitor) and immunofluorescence analysis of TDP-43 and HuR was performed. A-D: Untreated control, E-H: paraquat-treated, I-
L: paraquat and PD98059, M-P: paraquat and SB203580, Q-T: paraquat and SB600125. Green = TDP-43, red = HuR, blue = DAPI. Arrows indicate
SGs. Bottom panel indicates merged images from TDP-43 and HuR panels above. Bar = 10 μm. Representative images from three separate
experiments performed in duplicate or triplicate.
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File 6). No paraquat-induced SGs were observed in
HEK293 or human fibroblasts (GSM2069) (not shown).
Co-treatment of HeLa cultures with paraquat and
SP600125, dramatically reduced formation of TDP-43-
p o s t i v eS G s ,w i t ho n l yal i m i t e de f f e c to nt h ep r e s e n c e
of HuR-positive SGs analogous to SP600125 treatment
of SH-SY5Y cells (data not shown). These findings
demonstrate that paraquat induces TDP-43-positive SGs
in different cell-types and JNK-mediated control of
TDP-43 with SGs is not specific for one cell line but
appears to be a consistent feature of chronic stress-
induced SG formation.
JNK partially controls TDP-43 association with SGs in
arsenite stress
We examined whether inhibition of JNK also affected
localization of TDP-43 in cells exposed to sodium
arsenite, the most commonly used SG inducer. Sodium
arsenite is also known to induce JNK activation [41].
Initially, we compared the effect of sodium arsenite on
TDP-43 in SH-SY5Y cells at a concentration that
induced the same level of toxicity as paraquat did over-
night. 50 μM sodium arsenite overnight induced 58%
cell viability (compared to 57% cell viability in cells trea-
ted with 2 mM paraquat overnight, Additional File 1B).
However, this level of toxicity with sodium arsenite did
not cause cytosolic TDP-43 SGs. We also examined
short term treatment of cells with sodium arsenite (0.5
mM sodium arsenite for 1 hr) and while this induced
robust HuR SGs, few cells revealed TDP-43 co-localiza-
t i o n .G i v e nt h el a c ko fT D P - 4 3S G si nt h es o d i u m
arsenite-treated SH-SY5Y cells, we treated HeLa cells
with sodium arsenite (0.5 mM 1 hr). This treatment
induced widespread TDP-43 and HuR-positive SGs (Fig-
ure 8D-F). To determine if JNK activity was responsible
for TDP-43 accumulation in sodium arsenite-treated
cells, cultures were co-treated with SP600125 and para-
quat. Interestingly, we observed a 46% decrease in the
number of cells positive for TDP-43 SGs (Figure 8G-I).
As with inhibition of paraquat-treated SH-SY5Y cells,
SP600125 had little effect on HuR SGs (Figure 8G-I).
This partial, but significant, inhibition of TDP-43 locali-
zation to SGs by JNK inhibition suggests that JNK has a
role in TDP-43-SG interaction during acute sodium
arsenite treatment but other factors (e.g. other kinases)
are also involved.
JNK inhibition partially modulates aggregation of
transfected CTF-TDP-43
Next we investigated whether JNK controls aggregation
of transfected CTF-TDP-43 constructs. SH-SY5Y cells
were transfected with GFP-tagged vector control, full
length TDP-43, CTF-TDP-43 162-414 or CTF-TDP-43
219-414 for 48 hrs. As expected, no aggregates of TDP-
43 were observed in cells exposed to vector control (Fig-
ure 9A-B) or full length TDP-43 (Figure 9C-D). In con-
trast, CTF-TDP-43 162-414 or 219-414 induced
cytoplasmic aggregates in cells after 48 hr consistent
with previous reports [15] (Figure 9E-F and 9I-J). We
then treated cultures with SP600125 after 24 hr (to
allow transfection to stabilize) and examined the forma-
tion of TDP-43 aggregates after a further 24 hr incuba-
tion. While treatment with SP600125 did not reduce the
number of cells containing aggregated TDP-43, there
was a significant decrease in the number of aggregates
per cell in cultures transfected with TDP-43 162-414
(Figure 9K-L and 9M) and 219-414 (Figure 9G-H and
9M). ERK inhibition induced a small decrease in num-
ber of aggregates but this was not significant. These
findings suggested that the aggregation of these CTF-
TDP-43 fragments maybe partially affected by JNK. This
could be due to a role for basal JNK activity in modulat-
ing CTF-TDP-43 aggregation or alternatively, early
aggregation of the CTF-TDP-43 fragments could induce
cell stress that promotes further CTF-TDP-43 aggrega-
tion via JNK activation. This stress may then accelerate
aggregation in some cells.
JNK inhibition of TDP-43 SG formation is not due to
inhibition of 35 kDa CTF-TDP43 expression
Interestingly, while JNK inhibition blocked TDP-43
incorporation in SGs, it did not have a substantial effect
on inhibiting accumulation of diffuse cytosolic TDP-43
or prevent loss of nuclear TDP-43 induced by paraquat
treatment (Figure 6C-R). This finding provided further
support for the role of JNK in modulating cytosolic
TDP-43 incorporation into SGs rather than affecting
upstream processes leading to loss of nuclear TDP-43
and accumulation of TDP-43 in the cytosol. Additional
support for this was obtained when we examined the
effect of JNK inhibition on 35 kDa CTF-TDP-43 accu-
mulation. As shown in Figure 10, co-treatment of cul-
tures with the JNK inhibitor, actually led to an increase
in detectable levels of the3 5k D aC T F - T D P - 4 3r a t h e r
than inhibit its formation. This is consistent with the
data in Figure 4 demonstrating that the formation of
TDP-43-positive SGs was not fully prevented by inhibit-
ing 35 kDa CTF-TDP-43 formation using a caspase
inhibitor.
JNK inhibition blocks association of hnRNP K and TDP-43
with SGs
In order to obtain an insight into the potential mechan-
ism by which JNK controls TDP-43 association with
SGs during chronic stress, we examined co-localization
with other hnRNPs. Previous studies have reported that
TDP-43 binds to hnRNPs including hnRNP A1 and K
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trol the cellular localization and SG association of these
hnRNPs [31-36]. Analysis of TDP-43 and hnRNP A1
during paraquat stress did not reveal any co-localization
within SGs (Figure 10N-Q). In contrast, paraquat-trea-
ted cells revealed significant co-localization of hnRNP K
and TDP-43 in SGs (Figure 10F-I). Interestingly, JNK
inhibition fully blocked both TDP-43 and hnRNP K SG
accumulation (Figure 10J-M). As hnRNP K is known to
bind to TDP-43, associate with SGs and is phosphory-
lated by JNK, these findings suggest that modulation of
TDP-43 SG association by JNK could be controlled
through binding to hnRNP K. However, a comprehen-
sive analysis of hnRNP interactions with JNK and TDP-
43 is required to determine if this is the mechanism
occurring in paraquat-treated cells and other stress-
associated conditions leading to TDP-43 accumulation.
Discussion
Despite considerable research into TDP-43 in the past
five years, little is known about the earliest pathological
events associated with TDP-43 accumulation in ALS
ABC
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Figure 8 Treatment of HeLa cells with sodium arsenite induces JNK-dependent TDP-43 SGs. HeLa cells were treated for 1 hr with 0.5 mM
sodium arsenite and cells were examined for TDP-43 and HuR localization by immunofluorescence. A-C: untreated, D-F: sodium arsenite-treated,
G-I: sodium arsenite and SP600125. Green = TDP-43, red = HuR, blue = DAPI. Arrows indicate SGs. Bar = 10 μm. Representative images from
three separate experiments performed in duplicate or triplicate.
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Page 13 of 22and FTD. In this study, we have developed a model of
oxidative stress to investigate changes to endogenous
TDP-43 processing during cell stresses that reflect the
c h r o n i cn a t u r eo fA L Sa n dF T D .W es h o wh e r et h a t
mild stress induced by paraquat, a well-characterized
mitochondrial inhibitor and oxidative stress inducer,
induced changes to TDP-43 metabolism that closely re-
capitulated features observed in brain and/or spinal cord
of FTD and ALS patients. These changes included clear-
ance of TDP-43 from cell nuclei, accumulation of
diffuse TDP-43 in cytosol, aggregation into SGs, ubiqui-
tination of a portion of these SGs and increased expres-
sion of the 35 kDa CTF-TDP-43. These are all
considered important hallmarks of TDP-43 proteinopa-
thies [6,8]. Importantly, we also found these changes to
TDP-43 metabolism in differentiated neurons and addi-
tional cell-lines demonstrating that this was not a cell-
specific effect. In addition, short term treatment of cells
with paraquat (1 hr) had no effect on TDP-43, providing
strong support for chronic cell stress as an important
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Figure 9 Aggregation of CTF-TDP-43 162-414 and 219-414 in SY5Y cells is partially associated with JNK. SH-SY5Y cells were transfected
with GFP-tagged constructs for vector control (A-B), full length TDP-43 (C-D), CTF-TDP-43 219-414 (E-H) or CTF-TDP-43 162-414 (I-L). Green =
TDP-43-GFP, blue indicates DAPI. Arrows indicate TDP-43 aggregates. Bar = 10 μm. Cells were transfected with CTF-TDP-43 162-414 or 219-414
for 24 hr and co-treated with SP600125 (JNK inhibitor) (G-H and K-L) or PD98059 (ERK inhibitor) (not shown) for a further 24 hr. The number of
TDP-43-GFP aggregates per cell was determined (M). **p < 0.01. Representative images from two separate experiments performed in triplicate.
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Figure 10 JNK inhibition blocks association of hnRNP K and TDP-43 with SGs. SH-SY5Y cells were treated with 1 mM paraquat overnight in
the presence and absence of SP600125. A: Cells were immunoblotted for full length TDP-43 and 35 kDa CTF-TDP-43, B-Q: Cells were treated
with paraquat and SP600125 and examined for TDP-43, hnRNP K or hnRNP A1 by immunofluorescence. B-E: untreated, labeled for TDP-43
(green) and hnRNP K (red); F-I: paraquat-treated, labeled for TDP-43 (green) and hnRNP K (red); J-M: paraquat and SP600125, labeled for TDP-43
(green) and hnRNP K (red); N-Q paraquat-treated, labeled for TDP-43 (green) and hnRNP A1 (red). Right-hand panel indicates merged images
from TDP-43 and hnRNP panels. Arrows indicate SGs. Bar = 10 μm. Representative images from three separate experiments performed in
duplicate or triplicate.
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Page 15 of 22mediator of TDP-43 abnormal processing as observed in
ALS and FTD CNS tissues.
The key finding of this study was that cell kinase
activity and in particular, JNK activation, modulates
TDP-43 localization to SGs. This is the first report of
TDP-43 localization controlled by kinase activity. This
process is perhaps not surprising as previous reports
describe the nuclear-cytoplasmic movement and SG
localization of alternative hnRNPs and HuR. Habelhah
et. al., have shown that phosphorylation of hnRNP K by
ERK can modulate cytoplasmic accumulation [34]. In a
separate study they also demonstrated that hnRNP K is
phosphorylated by JNK at serine 216 and serine 353
[43]. Moreover, p38 phosphorylates hnRNP A1 inducing
SG localization [35,36]. There is also evidence that JNK
modulates localization and activity of HuR [44]. Impor-
tantly, several studies have shown that HuR and hnRNP
A1 and K as well as other hnRNPs directly bind TDP-
43 [25,42,45]. Interestingly this is mediated through
interaction at the C-terminal region of both proteins.
The C-terminal domain of TDP-43 is where the major-
ity of known ALS/FTD disease mutations have been
identified [11]. Moreover, there are key JNK phosphory-
lation consensus sites (Ser/Thr-Pro) within the C-term-
inal region of hnRNP K and HuR [43]. It is possible that
kinase (especially JNK) phosphorylation of hnRNPs
modulates interaction with TDP-43, thus mediating SG
association. Alternatively, specific phosphorylation of
h n R N P sm a ys i m p l yt a r g e tt h e mt oS G sa n dd u et o
TDP-43 association with these hnRNPs, it becomes
localized to SGs where hnRNPs are present. Further
support for an hnRNP-TDP-43 association was found in
our model where we showed that JNK inhibition
blocked localization of both TDP-43 and hnRNP K to
SGs. This is particularly interesting as hnRNP K is phos-
phorylated by JNK [43] and the phosphorylation site lies
within the hnRNP C-terminal domain that interacts
with TDP-43 in studies on other hnRNPs [42]. Further
support for this was shown by the fact that there was
no specific localization of hnRNP A1 with paraquat-
induced TDP-43 SGs in our study. Interestingly, the
only JNK phosphorylation consensus site on hnRNP A1
is in the N-terminal region (Ser7/Pro8) rather than in
the C-terminal region that would interact with TDP-43.
In addition to these findings, we observed that JNK inhi-
bition did not decrease CTF-TDP-43 generated by para-
quat treatment and in fact increased expression. This
indicated that JNK is more likely to be controlling loca-
lization of cytoplasmic TDP-43 to SGs similar to that
reported for other kinases and hnRNPs, rather than
modulating the formation of CTF-TDP-43. Whether it
is CTF-TDP-43 or full length TDP-43 or both that is
aggregating into SGs in this model remains to be seen.
Due to the loss of nuclear TDP-43 expression and the
fact that CTF-TDP-43 only accounted for approximately
10% of total TDP-43 on Western blots, strongly sug-
gested that the SGs probably contained full length TDP-
43 or a mixture of full length and CTF-TDP-43.
There must also be additional factors associated with
TDP-43 localization to SGs. JNK activation is not speci-
fic for paraquat and in fact, alternative mitochondrial
inhibitors used in this study also induce JNK activation
[38]. Phosphorylation of JNK is a common downstream
effect of oxidative and other cells stresses. The specifi-
city of paraquat to induce JNK-mediated localization of
TDP-43 may be related to specific sub-cellular localiza-
tion of activated JNK or modulation of additional co-
factors. Considerable investigation will be required to
delineate the specific processes induced by paraquat that
leads to JNK-mediated TDP-43 SG accumulation and
how these may relate to neurodegenerative diseases
such as ALS.
W h i l es o m er e c e n ts t u d i e sh a v er e p o r t e dap o s s i b l e
association between TDP-43 and TIA-1 [16,17], these
have been demonstrated with transfected cells and no
clear evidence of endogenous TDP-43-TIA-1 interaction
was identified. Moreover, TIA-1 does not contain JNK
consensus sites and there are no reports of JNK control
of TIA-1 localization. We believe that the data pre-
sented here are more consistent with a potential interac-
tion between TDP-43 and hnRNP K (Figure 11).
However, further studies will be required to demon-
strate specific interaction in this chronic stress model
and to determine if mutation of the C-terminal JNK
phosphorylation site on hnRNP K prevents TDP-43
association with SGs. It was also clear from our findings
that additional kinases can control TDP-43 and probably
a range of hnRNPs during stress. It will take a consider-
able effort to delineate the role of p38, ERK and addi-
tional kinases on TDP-43 accumulation both in vitro
and in vivo.
We also observed partial JNK-mediated control of
TDP-43 localization to SGs induced by sodium arsenite,
t h em o s tc o m m o nm e t h o du s e df o rS Gi n d u c t i o n .T h e
lack of complete inhibition of TDP-43 SG accumulation
was possibly related to the fact that sodium arsenite
rapidly induces SGs (minutes), while paraquat had no
effect on TDP-43 in short-term treatment even at very
high doses. This suggests that while sodium arsenite and
paraquat induce SGs and both involve JNK, there are
different cellular mechanisms involved in short term
and longer term SG formation. This is consistent with
the previously reported concept that different stresses
have diverse affects on SG formation [18]. In this con-
text, we feel that our paraquat-based mild oxidative
stress model is an important tool for delineating TDP-
43 SG association as it occurs under mild stress condi-
tions expected in chronic neurodegenerative diseases
Meyerowitz et al. Molecular Neurodegeneration 2011, 6:57
http://www.molecularneurodegeneration.com/content/6/1/57
Page 16 of 22and better re-capitulates the features of TDP-43 protei-
nopatheis than sodium arsenite. It is possible that the
latter, (ie acute sodium arsenite exposure) rapidly drives
SG formation in cells that are experiencing high levels
of toxicity. As shown in Additional File 1B, treatment
with 500 μM sodium arsenite overnight results in almost
total loss of cell viability as compared to only 15%
decrease in viability with 1 mM paraquat overnight.
Whether JNK directly modulates TDP-43 is not
known. TDP-43 does not contain known consensus sites
for JNK, p38 or ERK. However, it does contain two
putative JNK binding domains (RxxxKxxxLxV and
KxxRxxxxVxF) at 98-108 and 224-235 respectively. It
remains a possibility that JNK binds to TDP-43 and acts
as a scaffolding protein affecting SG localization. While
no other studies have demonstrated a TDP-43-JNK
association, a previous report described a role for a
JNK-interacting protein, WDR62 in SG formation [41].
Interestingly, they reported that inhibition of JNK dur-
ing sodium arsenite treatment increased the number of
SGs (in HEK293 cells) but decreased the size of the
granules. This is in contrast to our finding in HeLa cells
where we found a partial decrease in TDP-43 SG asso-
ciation but no observable changes to HuR SG formation
with SP600125. In addition, JNK inhibition did not
block SG formation by paraquat as determined by HuR
staining but did block TDP-43 and hnRNP K localiza-
tion. However, these differences are again likely to be
due to acute sodium arsenite treatment compared to
longer paraquat treatment used here, different cell lines
and different markers of SGs eg HuR and TIA-1. Impor-
tantly, the findings show that different model systems
may give a range of different outcomes and in terms of
understanding TDP-43 pathological changes, it will be
important to ensure that the model gives an accurate
reflection of the disease processes. With that in mind,
we are currently investigating TDP-43 metabolism in
primary neuronal and glia cell cultures as this may be a
more accurate model system to understand TDP-43 SG
dynamics.
T h er o l ef o rs t r e s sk i n a s e ss u c ha sJ N Ka n dp 3 8i n
ALS has been suggested through recent studies. SOD1
ALS models have shown enhanced activity of these
k i n a s e sa sw e l la sm o d u l a t i o no fE R K[ 4 6 - 5 0 ] .I n t e r e s t -
ingly, a recent report by Ayala et al. [51] found ERK
aggregates in stressed cells and ALS tissues and inhibi-
tion of ERK lead to increased TDP-43 aggregation in
cultures. While these affects appear to contrast with our
own findings, the differences may reflect different inten-
sity and form of stress as well as different cell models
and time frame. It will be important to determine the
kinetics of ERK and other kinases activation across the
disease course in ALS. A single report on JNK activation
in ALS patients has described increased activity in astro-
cytes but not neurons in spinal cord of these patients
[52]. We found that paraquat induced TDP-43 aggrega-
tion in both neuronal-like and astroglial cell lines in this
study. Whether JNK or additional kinases are associated
with early changes to TDP-43 accumulation in vivo is
not known due to the difficulty of obtaining relevant
early disease tissues. It is likely that with the current
development of multiple animal models of TDP-43 pro-
teinopathy that re-capitulate human disease neuro-
pathology, we will be able to determine the early events
in TDP-43 processing. It is also uncertain what role
hnRNPs have in determining TDP-43 aggregation in
ALS or FTD. While a large number of hnRNPs have
been shown to bind to TDP-43 and many are associated
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Figure 11 Schematic of proposed stress-mediated TDP-43 accumulation into SGs. Chronic cell stress (eg oxidative stress) induces activation
of stress kinases such as JNK. This may phosphorylate hnRNPs such as hnRNP K resulting in phosphoryated forms (p-hnRNP). This could
modulate interaction with TDP-43 and association with SGs. Prolonged stress may lead to progression of SGs to protein aggregates containing
TDP-43 and subsequent cell toxicity.
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Page 17 of 22with SGs, their role in ALS and FTD has not been
established. It is important to note, however, that several
recent studies have shown that TDP-43 and FUS are
associated with SG marker proteins in ALS tissues
[17,24].
An important outcome from this study is that kinases
may be an important target for therapeutic intervention
in ALS and FTD. Should further studies show that
kinase activation controls TDP-43 aggregation especially
early in disease, it may be possible to inhibit this process
with kinase inhibitors. Interestingly, the only approved
treatment for slowing ALS disease progression, Riluzole,
is known to modulate stress kinase activity [53], and
kinase modulators have been discussed previously as
possible therapeutic agents for ALS.
Conclusions
In summary, it has been difficult to accurately model
endogenous aberrant TDP-43 in cell models. Treatment
of cells with sodium arsenite or osmotic stress induces
robust TDP-43 containing SGs however, these models
have not recapitulated the broad features of TDP-43
mis-metabolism observed in ALS and FTD brain and
spinal cord tissues in a manner consistent with transfec-
tion of CTF-TDP-43 constructs. The latter however, are
likely to be prone to spontaneous aggregation when
over-expressed and may not represent an accurate
model of the cellular control of TDP-43 processing dur-
ing chronic stress. Likewise, although studies with
mutant TDP-43 constructs can help to understand the
disease processes, the majority of ALS and FTD cases
a r es p o r a d i ca n dp r o b a b l yi n v o l v eo n l ye n d o g e n o u s ,
non-mutated TDP-43. Our model has recapitulated a
number of features of aberrant endogenous TDP-43
metabolism including loss of nuclear staining, accumula-
tion of diffuse cytoplasmic TDP-43, formation of CTF-
TDP-43, aggregation into SGs and ubiqitination of a
portion of these SGs indicating the possible transition to
irreversible protein aggregates. The aggregation of TDP-
43 into SGs is controlled by JNK and SG formation is
controlled by additional kinases and these factors are
associated with chronic stress. Future studies will be
required to fully delineate the mechanism by which
kinases control TDP-43 aggregation and whether this is
involved in TDP-43 aggregation in vivo. These findings
may have important implications for identifying poten-
tial therapeutic targets for intervention in ALS and FTD.
Methods
Materials
4’,6’ Diamino-2-phenylindole dihydrochloride (DAPI)
was obtained from Invitrogen (Mount Waverley, Vic-
toria, Australia). (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT), N, N’-dimethyl-4,4’-
bipyridinium dichloride (paraquat), rotenone, 1-methyl-
4-phenylpyridinium (MPP+ ) ,s o d i u ma z i d e ,s o d i u m
arsenite, 3-nitropropionic acid (3-NP) and 3-Morpholi-
nosyndnomine (SIN-1) were from Sigma Aldrich (Syd-
ney, NSW, Australia) and LDH assay kit was purchased
from Roche Diagnostics (Castle Hill, NSW, Australia).
SP600125, PD98095, SB203580 were purchased from
Merck Biosciences (Melbourne, Victoria, Australia). BI-
78D3 and D4476 were purchased from Tocris
Bioscience (Ellisville, Melbourne, Victoria, Australia). Z-
VAD-fmk was obtained from Promega (Sydney,
Australia).
Polyclonal TDP-43 antisera were purchased from Pro-
teintech Group (Chicago, IL, USA). Monoclonal antisera
to the phosphorylated form of TDP-43 (ser409/410)
were obtained from Cosmo Bio (Tokyo, Japan). Antisera
to ubiquitin were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Monoclonal antisera to hnRNP A1 and
hnRNP K were purchased from Abcam (Waterloo, Aus-
tralia). Monoclonal antisera to HuR were obtained from
Invitrogen (Mount Waverley, Victoria, Australia). Anti-
sera to total and phosphorylated forms of p38, ERK and
JNK, as well as antibodies to actin and GAPDH were
purchased from Cell Signalling Technologies (Arundel,
Queensland) or BD Bioscience (North Ryde NSW,
Australia).
Methods
Cell Culture
The cell lines used in this study were human neuroblas-
toma SH-(SY5Y) cell line, human epithelial HeLa cell
line, human embryonic kidney cell line (HEK293),
human fibroblast cell line (GSM2069) and human astro-
glial U87MG cell line. Cells were passaged and main-
tained in DMEM plus 5% FBS (HeLa and HEK293
cells), DMEM/F12 plus 10% FBS (SH-SY5Y and U87MG
cells) or BME plus 10% FCS (GSM2069 fibroblasts). To
induce differentiation, SY5Y cells were treated with 10
μM retinoic acid for 7 days. Differentiation was con-
firmed by morphological changes (neurite extension)
and up-regulated expression of synaptophysin, tyrosine
hydroxylase and VMAT2. All cells were grown in 5%
CO2 at 37°C.
Cell viability and cell lysis assays
Assays for cell viability (MTT) and cell lysis (LDH) were
performed as previously described [28].
Exposure of cell to stress
Undifferentiated cells were grown in 24 or 6-well plates
or on 12 mm coverslips (for immunofluorescence) for
2-3 days before experiments (~80% confluent). Differen-
tiated SH-SY5Y cells were cultured in the presence of
retinoic acid for 7 days before experiments. Inducers of
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tive stress (rotenone, 3-N P ,s o d i u ma z i d e ,M P P + ,
sodium arsenite and paraquat) were prepared in dH2O
and added at indicated concentrations and the medium
was briefly mixed by aspiration. Incubations were per-
formed for periods stated in individual experiments.
Where indicated, cells were co-treated with kinase inhi-
bitors (SP600125 (JNK), BI-78D3 (JNK), PD98095 &
U0126 (ERK), SB203580 & SB202190 (p38), D4476
(casein kinase 1) from stock solutions prepared at 10
mM in DMSO. Control cultures were treated with vehi-
cle alone. For immunoblotting, cells were harvested into
Phosphosafe Extraction Buffer (Merck Biosciences, San
Diego, CA, USA) containing protease inhibitor cocktail
( R o c h eD i a g n o s t i c s )a n ds t o r e da t- 8 0 ° Cu n t i lu s e .F o r
immunofluorescence studies, cells were grown on glass
coverslips and fixed by treating with 4% paraformalde-
hyde for 30 min.
siRNA knockdown of JNK
ON-TARGETPlus human JNK1 siRNA pool, JNK2
siRNA pool and non-targeting siRNA pool (D-001810-
10-20, Negative control) were obtained from Dharma-
con and resuspended in RNAase free water at 100 μM.
Human JNK1 siRNA pool target sequences were 5’-
GCCCAGUAAUAUAGUAGUA-3’,5 ’-GGCAUGGG-
CUACAAGGAAA-3’,5 ’-GAAUAGUAUGCGCAG-
CUUA-3’ and 5’-GAUGACGCCUUAUGUAGUG-3’.
Human JNK2 siRNA pool target sequences were 5’-
UCGUGAACUUGUCCUCUUA-3’,5 ’-AGCCAACUGU-
GAGGAAUUA-3’,5 ’-GGCUGUCGAUGAUAGGUUA-
3’ and 5’-GAUUGUUUGUGCUGCAUUU-3’. Cells were
seeded on coverslips at 5 × 10
4 cells per cm
2 in Opti-
MeM to give 40% confluency on treatment day. Cells
were transfected with pooled JNK1 and JNK2 siRNA or
Negative control siRNA in Lipfectamine 2000 for 5 hr at
room temperature (0.5 μg RNA per well). Media was
then replaced with normal SY5Y growth medium over-
night before treatment with paraquat (1 mM) overnight.
Cells were then collected for Western blot for JNK or
fixed for immunofluoresence of TDP-43 and HuR.
Western blot analysis of protein expression and
phosphorylation
Cell lysates prepared in Phosphosafe Extraction Buffer at
equal protein concentration were mixed with electro-
phoresis SDS sample buffer and separated on 12% SDS-
PAGE Tris-Glycine gels. Proteins were transferred to
PVDF membranes and blocked with 4% skim milk solu-
tion in PBST before immunoblotting for total or phos-
pho-specific proteins. For detection of total TDP-43,
membranes were probed with polyclonal antisera
(1:1500) against TDP-43. Secondary antiserum was rab-
bit-HRP at 1:5,000 dilution. For detection of total and
phospho-forms of JNK, ERK and p38, membranes were
probed with anti-JNK, anti-ERK or anti-p38 (each at
1:5000) and antisera to phospho-forms of each protein
(each at 1:5000). Blots were developed using GE Health-
care ECL Advance Chemiluminescence and imaged on a
Fujifilm LAS3000 imager (Berthold, Bundoora, Austra-
lia). Expression of GAPDH or actin was determined
using antisera at 1:5000 and 1:3000 respectively for pro-
tein loading controls where necessary.
Immunofluorescence analysis
SH-SY5Y cells were grown on 12 mm diameter cover-
slips and treated with stresses as indicated. Cells were
fixed with 4% w/v paraformaldehyde in PBS for 30 min
and permeabilized with 90% chilled methanol for 5
m i n .A f t e rb l o c k i n gf o r1h rw i t h1 0 %n o r m a lg o a t
serum, cells were incubated with primary antibody for
total TDP-43 (1:1500), ubiquitin (1:150), HuR (1:50),
hnRNP A1 (1:200) or hnRNP K (1:200) for 2 hr at
room temperature or overnight at 4°C. This was fol-
lowed by labeling with secondary AlexaFluor or FITC
goat anti-mouse or anti-rabbit antisera at 1:500 for 2
hr at room temperature or overnight at 4°C. After
washing, the coverslips were incubated with DAPI at
0.5 μg/ml for 5 min and analyzed using a Leica
inverted microscope with Zeiss Axiocam digital cam-
era. Images shown are representative of multiple fields
and triplicate coverslips per experiment. TDP-43 and
HuR-positive stress granules (SGs) were counted in
cultures where indicated. A minimum of 500 cells was
counted across multiple fields of view (and multiple
coverslips) for each treatment. The number of TDP-43
and HuR-positive SGs were counted in these cells. The
total number of cells was divided by the total number
of SGs to provide a measure of mean SGs per cell.
SGs were not observed in untreated cells.
Preparation of TDP-43 plasmids
Plasmid DNA corresponding to GFP-tagged full-length
wild-type (WT) TDP-43 (pEGFP-TDP WT), C-terminal
fragments of TDP-43, (pEGFP-TDP 162-414 and
pEGFP-TDP 219-414) or empty expression vector
pEGFP-C1 were prepared as described by Nonaka et al.
[15]. Briefly, plasmid DNA was used to transform MAX
Efficiency
® DH5a™ Competent Cells (Invitrogen,
Mount Waverley, Victoria, Australia) as described by
the manufacturer. Transformants were grown and colo-
nies were picked based on kanamycin-resistance and
grown in liquid culture for subsequent plasmid purifica-
tion. DNA was purified using the Wizard
® Plus Midi-
prep DNA Purification System (Promega Corporation)
as per manufacturer’s instructions. DNA was quantified
and TDP-43 inserts were identified positively by diges-
tion with BamHI and XhoI.
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SH-SY5Y cells were seeded at 2 × 10
5 cells per well in
24 well-plates on coverslips. Cells were transfected 24 hr
after seeding with the pEGFP-C1 empty vector, pEGFP-
TDP WT, pEGFP-TDP 162-414 and pEGFP-TDP 219-
414 using Attractene (Qiagen) according to manufac-
turer’s instructions. After 48 hr incubation, cells were
fixed with 4% w/v paraformaldehyde in PBS for 30 min.
and permeabilized with 90% chilled methanol for 5 min.
After washing, the coverslips were incubated with DAPI
at 0.5 μg/ml for 5 min and analyzed using a Leica
inverted microscope with Zeiss Axiocam digital camera.
Expression of TDP-43 was determined by the EGFP-
tagged construct. Efficiency of transfection with pEGFP-
C1 vector was approximately 20-25%.
Statistical analysis
All data described in graphical representations are mean
± standard error of the mean (SEM) unless stated from
a minimum of three experiments. Results were analysed
using a two-tailed Student’s t-test.
Additional material
Additional file 1: SH-SY5Y cell viability after exposure to nitrosative
or oxidative stress inducers. SH-SY5Y cells were treated with indicated
compounds overnight and cell viability was measured with the MTT
assay. A: Mild neurotoxicity was induced with all compounds tested.
Concentrations were SIN-1, 0.1 mM; arginine, 1 mM; Paraquat, 1 mM and
2 mM; 3-NP, 1 mM; MPP+, 2 mM; sodium azide, 5 mM and rotenone,
0.075 mM. B: Comparison of neurotoxicity induced by 1 and 2 mM
paraquat or 0.05 mM and 0.5 mM arsenite treatment overnight. *p <
0.05, **p < 0.01. n = three experiments.
Additional file 2: Treatment of SH-SY5Y neurons induces SG
formation associated with mild toxicity. Non-differentiated (A-C)o r
differentiated (D-K) were treated with 0-2 mM (A-C) or 1 mM (D-K)
paraquat overnight. A: Cell viability was determined by MTT assay. B: Cell
death was determined by LDH assay. C: Stress granules (SGs) per cell
were determined. *p < 0.05, **p < 0.01. D-K: TDP-43 and HuR
immunofluorescence was examined in retinoic acid-differentiated
neurons after treatment with 1 mM paraquat. Green = TDP-43, Red =
HuR, Blue = DAPI. Arrows indicate SGs. Bar = 10 μm. G and K represent
merged images. n = three experiments.
Additional file 3: Paraquat treatment did not induce
phosphorylation of TDP-43 in SGs. Cells were treated overnight with 1
mM paraquat and examined for phosphorylated TDP-43 by
immunofluorescence. A-C: untreated, D-F: paraquat treated. Green =
HuR, Red = phospho-TDP-43, blue = DAPI. Bar = 10 μm. G: Immunoblot
for phospho-TDP-43 (p-TDP-43) in paraquat-treated cultures.
Representative images from three separate experiments.
Additional file 4: Treatment of SH-SY5Y cells with different
mitochondrial inhibitors did not induce HuR SGs. Cells were treated
with vehicle control (A-B), 2 mM MPP+ (C-D), 1 mM 3-NP (E-F), 0.075
mM rotenone (G-H) or 5 mM sodium azide (I-J). Cells were analyzed for
HuR localization by immunofluorescence. Red = HuR, blue = DAPI. Bar =
10 μm. K: Treatment with 1 mM paraquat (PQ) overnight induced
phospho-JNK (pJNK) and this was inhibited by co-treatment with 20 μM
SP600125. Representative images from three separate experiments.
Additional file 5: Treatment of SH-SY5Y cells with siRNA to JNK
inhibits TDP-43 accumulation in SGs. A: Cells were treated with
pooled siRNA against JNK1 and JNK2 or with negative control siRNA and
examined for JNK expression. siRNA to JNK significantly reduced
expression of JNK1 and JNK2. B-E: Untreated control cells. F-I: cells
treated with negative control siRNA reveal TDP-43 and HuR-positive SGs.
J-M: Cells treated with siRNA to JNK reveal lack of TDP-43 but not HuR-
positive SGs. Green = TDP-43, red = HuR, blue - DAPI. Arrows indicate
SGs. Bar = 10 μm. Representative images from two-three separate
experiments performed in triplicate.
Additional file 6: Treatment of U87MG astroglial and HeLa
epithelial cells with paraquat results in TDP-43 SGs. U87MG (A-F)
and HeLa (G-L) cells were treated overnight with 1 mM paraquat and
analyzed for TDP-43 and HuR localization by immunofluorescence. A-C:
Untreated U87MG cells, D-F: paraquat-treated U87MG cells, G-I:
untreated HeLa cells, J-L: paraquat-treated HeLa cells. Green = TDP-43,
red = HuR, blue = DAPI. Arrows indicate SGs. Bar = 10 μm.
Representative images from three separate experiments performed in
duplicate or triplicate.
Abbreviations
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